Navigation Links
NIH stem cell guidelines should be modified, UCSF team reports
Date:2/18/2010

A UCSF team, led by bioethicist Bernard Lo, MD, recommends that the National Institutes of Health ethics guidelines for embryonic stem cell research be modified to better protect the rights of individuals donating egg or sperm to patients undergoing in vitro fertilization.

The recommendation is reported in the February 19, 2010 issue of Science.

Third parties frequently donate sperm and egg, or "gametes," for patients attempting to create embryos in the in vitro fertilization clinic.

Under current practice in the United States, gamete donors sign a form giving the IVF patient unrestricted legal authority to determine how to dispose of any embryos that may be leftover following fertility treatments. Donor banks and IVF clinics are not required to brief gamete donors about the various options for disposition, which include donating the embryos for stem cell research, thereby enabling scientists to derive new human embryonic stem cell lines; discarding the embryos, or donating them to other IVF patients.

While many state, national, and international scientific committees and agencies have recommended that third-party gamete donors give formal "informed consent" for stem cell research with embryos remaining after infertility treatment, the NIH did not stipulate this requirement in its guidelines issued in March 2009. As these guidelines determine which human embryonic stem cell (hESC) lines may be studied under NIH research grants which are expected to play a growing role in funding stem cell research the ethical implications are significant, says Lo, chair of the UCSF Gamete, Embryonic Stem Cell Research Committee, members of which published the Science paper.

"We urge the NIH to revise its guidelines to require that gamete donors be advised that embryos containing their sperm or egg could be used for embryonic stem cell research, before they grant dispositional authority over embryos to the IVF patient," he says. "Because some gamete donors may not approve of embryonic stem cell research, we consider this the ethically appropriate position."

In their paper, the team recommends a process that is less complex than the detailed "informed consent" process carried out when IVF patients donate embryos for research. They suggest the disclosure to gamete donors may be made through oral discussion or brochures before donors sign a form authorizing the IVF patient to determine the disposition of embryos.

Importantly, says Lo, the gamete donors' instructions would not disrupt the IVF process. IVF patients would learn of a gamete donor's restrictions in advance of selecting embryos for IVF treatment, and could select other gamete donors if not satisfied with the donors' disposition restrictions.

The recommendation is consistent with that of the National Academy of Sciences and the International Society for Stem Cell Research says Lo, a member of the ethics committee of the ISSCR, and the co-chair of the Standards Working Group of the California Institute for Regenerative Medicine.

"It would be highly desirable to have consistency among standards and regulations," he says. "If such harmonization were achieved, many university Institutional Review Boards and other research oversight bodies would likely allow NIH-eligible human embryonic stem cell lines to be used for any otherwise acceptable hESC research."

"It's critical that we consider all parties involved in the creation of embryos and honor their wishes," says co-author Arnold Kriegstein, MD, PhD, director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF.

"The field of human embryonic stem cell research offers enormous promise for patients suffering from devastating diseases. We want to build this field on an ethical foundation of which we can be proud."

Exceptions to the guideline could be justified for hESC lines already in existence if there were strong scientific reasons to use the cell lines and the third-party gamete donor had granted rights to the IVF patient to determine disposition of the embryos.


'/>"/>

Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Source:Eurekalert

Related biology news :

1. UNC study questions FDA genetic-screening guidelines for cancer drug
2. 2 carotid artery stenting studies show results comparable to AHA guidelines
3. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
4. NHLBI issues first US von Willebrand Disease clinical practice guidelines
5. New guidelines for treating rheumatoid arthritis
6. Study finds ATV guidelines inadequate
7. Guidelines urge physical activity during pregnancy
8. The International Society for Stem Cell Research releases new guidelines
9. Publication sets guidelines across cancer therapies: Ensuring the best in patient management
10. Coral Disease Handbook: Guidelines for Assessment, Monitoring and Management
11. First comprehensive guidelines for managing medullary thyroid carcinoma published in Thyroid journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/19/2017)... and PUNE, India , January 19, 2017 ... "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the global ... a CAGR of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... high-level security for both public and private sectors. ... ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... Aethlon Medical, Inc. (Nasdaq: AEMD ... validated the ability of the Aethlon Hemopurifier® to capture ... in immune-suppressed sepsis patients and also contribute to organ ... of the study was to validate the in ... and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. ...
(Date:2/22/2017)... Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 ... ) today announced its financial results for the ... "Our annual 2016 financial results reflect continued ... earnings exceeded $700 million," said Martine Rothblatt, Ph.D., ... financial results strengthen our ability to develop and ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex Biosciences announced ... automated benchtop system for collecting intact circulating tumor cells (CTCs) that are shed ... Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San Francisco). , The ...
(Date:2/21/2017)... Chicago, IL (PRWEB) , ... ... ... launch of the Life -Sciences division, Treximo will pair its $200M operational ... class, results-based consulting and project management in areas affecting quality and operational ...
Breaking Biology Technology: